Search Results

September 30, 2014

Johnson & Johnson Announces Agreement To Acquire Alios BioPharma

Acquisition Strengthens Existing Pipeline in Viral Diseases

September 24, 2014

Study Observed Association between JANSSEN® CONNECT® Injection Centers and Increased Adherence to Healthcare Provider-Ordered Janssen Long-Acting Treatment for People with Schizophrenia

JANSSEN® CONNECT® program seeks to provide people living with schizophrenia information and assistance to support healthcare provider-ordered long-acting antipsychotic treatment

Innovative Medicine

September 12, 2014

Johnson & Johnson Announces New Grant to Harvard Medical School to Combat Drug-Resistant Tuberculosis

New collaboration will help address significant global unmet needs in pediatric drug-resistant tuberculosis (DR-TB) treatment and optimize use of existing DR-TB treatments

Global health equity

September 3, 2014

Johnson & Johnson Responds to Ebola Crisis with Commitment to Accelerate Vaccine Program in Collaboration with the US National Institutes of Health (NIH) and Provide Humanitarian Relief Aid

Innovative Medicine

September 2, 2014

New Data Show Once-Daily XARELTO® May Be an Alternative to Vitamin K Antagonists in Treating Atrial Fibrillation Patients Undergoing Elective Cardioversion

X-VeRT Study Results Presented as a Hot Line Session at the ESC Congress 2014 and Published in European Heart Journal

Research

August 29, 2014

Janssen Expands EXPLORER Global Cardiovascular Research Program to Evaluate the Role of XARELTO® in Addressing Critical Medical Needs

New Studies Grow XARELTO® Clinical Development Program to More Than 275,000 Patients

Research

August 26, 2014

Janssen Diagnostics Expands Research Portfolio to Include Next-Generation Sequencing

Enhanced Offering to Enable ‘Dynamic Monitoring’ in Cancer Research

Innovative Medicine

August 25, 2014

Janssen Affiliate Cilag GmbH International Acquires Covagen AG

Clinical Candidate COVA 322 and FynomAb® Technology Platform Further Strengthen Immunology Portfolio and Capabilities

Innovative Medicine

August 8, 2014

U.S. FDA Approves INVOKAMET™ (canagliflozin/metformin HCl) for the Treatment of Adults with Type 2 Diabetes

In Phase 3 studies, INVOKANA® plus metformin lowered blood sugar and reduced secondary endpoints of body weight and systolic blood pressure to a greater degree than metformin alone

Innovative Medicine

August 5, 2014

Janssen Launches Online Healthy Minds Video Series

Promotes Knowledge of Brain Disorders and Encourages Anti-Stigma Efforts

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine